CBCS - about us
The Core Facility at Karolinska Institutet is one of six CBCS nodes and a national infrastructure established in 2010 and located in Alfa-5 at SciLifeLab, Campus Solna. CBCS KI provides expertise and instrumentation for assay development and screening (BSL-2 and BSL-3) and enabling chemistry support, including medicinal synthetic and computational chemistry. The facility also accommodates the Compound Center hosting a collection of more than 350 000 small molecules.
The scientists at CBCS have diverse backgrounds from both academia and the pharmaceutical industry and solid experience in assay development, screening and development of bioactive molecules.
Meet our team
Platform Director
Assay Development and Screening
Hanna Axelsson
Project ManagerWeiyingqi Cui
Research Infrastructure SpecialistFrancesco Massai
Research Infrastructure SpecialistKun Qian
Research Infrastructure SpecialistMedicinal Chemistry
Martin Haraldsson
ResearcherTobias Koolmeister
Research EngineerMichaela Vallin
Project ManagerComputational Chemistry and Cheminformatics
Flavio Ballante
Research SpecialistMats Dahlberg
Database CoordinatorCompound Center
Maria Adolfsson
Laboratory TechnicianElisabeth Olsson
Research EngineerÅsa Slevin
Research EngineerContact and visit us
Visiting address: SciLifeLab, Tomtebodavägen 23a, 171 65 Solna
Postal address: Karolinska Institutet, CBCS, SE-117 77 Stockholm
Contact us: to discuss a project
Book our services: Compund Center Order Portal
Collaborations
CBCS has engaged in a partnership with AstraZenecas Open Innovation program to mediate academic collaborators’ access to AstraZeneca’s annotated small molecule compound library.
CBCS is an active partner in the Nordic Chemical Biology Network and subnetworks like the Nordic High content screening community.
Through CBCS, Sweden is a member of EU-OPENSCREEN, the European Infrastructure of Open Screening Platforms for Chemical Biology.
Further, CBCS is an associated partner to the Innovative Medicines Initiative (IMI) program EUbOPEN.